Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04713553
Recruitment Status : Completed
First Posted : January 19, 2021
Last Update Posted : August 5, 2021
Information provided by (Responsible Party):
BioNTech SE

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : July 22, 2021
Actual Study Completion Date : July 22, 2021